Testing effectiveness (Phase 2)Study completedNCT02954055What this trial is testingMEtronomic TrEatment Option in Advanced bReast cAncerWho this might be right forBreast Cancer ETOP IBCSG Partners Foundation 140
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07539753What this trial is testingBrain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain MetastasesWho this might be right forBreast CancerBrain MetastasesHR+/HER2- Breast Cancer Nanfang Hospital, Southern Medical University 46
Testing effectiveness (Phase 2)Looking for participantsNCT01042379What this trial is testingI-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerWho this might be right forBreast NeoplasmsBreast CancerBreast Tumors+8 more QuantumLeap Healthcare Collaborative 5,000
Testing effectiveness (Phase 2)Ended earlyNCT01495247What this trial is testingPhase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast CancerWho this might be right forInoperable Locally Advanced Breast CancerMetastatic Breast Cancer (MBC) Novartis Pharmaceuticals 18
Testing effectiveness (Phase 2)Study completedNCT02401347What this trial is testingPhase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid TumorsWho this might be right forAdvanced Breast CancerHER2/Neu NegativeTriple-Negative Breast Cancer Melinda Telli 21
Testing effectiveness (Phase 2)Study completedNCT04072952What this trial is testingA Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast CancerWho this might be right forBreast Cancer Arvinas Estrogen Receptor, Inc. 217
Large-scale testing (Phase 3)Ended earlyNCT01303679What this trial is testing1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast CancerWho this might be right forFirst Line Metastatic Breast Cancer ARCAGY/ GINECO GROUP 117
Early research (Phase 1)Study completedNCT03685331What this trial is testingHOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast CancerWho this might be right forMetastatic Breast CancerLocally Advanced Breast CancerAdvanced Breast Cancer+2 more Abramson Cancer Center at Penn Medicine 9
Post-approval studies (Phase 4)Study completedNCT05631795What this trial is testingStudy to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine TreatmentWho this might be right forAdvanced Breast Cancer Novartis Pharmaceuticals 40
Testing effectiveness (Phase 2)Study completedNCT06375707What this trial is testingFirst-Line Ribociclib Plus Endocrine Therapy Versus Chemotherapy With or Without Subsequent Endocrine Therapy in Patients With Rapidly Progressive HR-Positive/HER2-Negative Advanced Breast CancerWho this might be right forAdvanced Breast Cancer The First Affiliated Hospital with Nanjing Medical University 74
Testing effectiveness (Phase 2)Looking for participantsNCT06649331What this trial is testingPlatform Study of ADC Rechallenge in ADC-treated Metastatic Breast CancerWho this might be right forAdvanced Breast CancerMetastatic Breast CancerTriple Negative Breast Cancer (TNBC)+2 more Fudan University 160
Large-scale testing (Phase 3)Active Not RecruitingNCT06760637What this trial is testingStudy of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic DiseaseWho this might be right forBreast Cancer Pfizer 1,035
Early research (Phase 1)Ended earlyNCT07214662What this trial is testingEvaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast CancerWho this might be right forBreast Cancer Genentech, Inc. 3
Testing effectiveness (Phase 2)UnknownNCT03202862What this trial is testingThe Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast CancerWho this might be right forBreast Neoplasms Fudan University 50
Large-scale testing (Phase 3)UnknownNCT03927456What this trial is testingSHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast CancerWho this might be right forAdvanced Breast Cancer Jiangsu HengRui Medicine Co., Ltd. 357
Testing effectiveness (Phase 2)UnknownNCT05420779What this trial is testingEvaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA MutationsWho this might be right forBreast Cancer Metastatic Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. 125
Not applicableNot Yet RecruitingNCT06711094What this trial is testingAlbumin-bound Paclitaxel、Dalpiciclib and AI in ER-Low (1%-10%) HER2-ABCWho this might be right forHR+/HER2- Advanced Breast Cancer Fujian Medical University 52
Post-approval studies (Phase 4)Study completedNCT04707196What this trial is testingAbemaciclib in Indian Women With Advanced Breast CancerWho this might be right forBreast NeoplasmsNeoplasm Metastasis Eli Lilly and Company 200
Testing effectiveness (Phase 2)Study completedNCT00479674What this trial is testingPhase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast CancerWho this might be right forBreast Cancer Duke University 41
Testing effectiveness (Phase 2)Ended earlyNCT00452140What this trial is testingPhase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine TreatmentWho this might be right forMetastatic Breast CancerAdvanced Breast Cancer Neovii Biotech 40